RS61307B1 - Rpgr genska terapija za pigmentnu retinopatiju - Google Patents

Rpgr genska terapija za pigmentnu retinopatiju

Info

Publication number
RS61307B1
RS61307B1 RS20201416A RSP20201416A RS61307B1 RS 61307 B1 RS61307 B1 RS 61307B1 RS 20201416 A RS20201416 A RS 20201416A RS P20201416 A RSP20201416 A RS P20201416A RS 61307 B1 RS61307 B1 RS 61307B1
Authority
RS
Serbia
Prior art keywords
rpgr
human
viral vector
protein
seq
Prior art date
Application number
RS20201416A
Other languages
English (en)
Serbian (sr)
Inventor
Michael A Sandberg
Basil Pawlyk
Tiansen Li
Xinhua Shu
Alan Finlay Wright
Robin Ali
Original Assignee
Massachusetts Eye & Ear Infirmary
Ucl Business Ltd
The Government Of The United States Of America As Represented By The Secretary Department Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary, Ucl Business Ltd, The Government Of The United States Of America As Represented By The Secretary Department Of Health filed Critical Massachusetts Eye & Ear Infirmary
Publication of RS61307B1 publication Critical patent/RS61307B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
RS20201416A 2014-07-24 2015-07-17 Rpgr genska terapija za pigmentnu retinopatiju RS61307B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24
PCT/US2015/040866 WO2016014353A1 (en) 2014-07-24 2015-07-17 Rpgr gene therapy for retinitis pigmentosa
EP15825383.1A EP3191139B1 (en) 2014-07-24 2015-07-17 Rpgr gene therapy for retinitis pigmentosa

Publications (1)

Publication Number Publication Date
RS61307B1 true RS61307B1 (sr) 2021-02-26

Family

ID=55163577

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20201416A RS61307B1 (sr) 2014-07-24 2015-07-17 Rpgr genska terapija za pigmentnu retinopatiju
RS20240901A RS65909B1 (sr) 2014-07-24 2015-07-17 Rpgr genska terapija za pigmentnu retinopatiju

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20240901A RS65909B1 (sr) 2014-07-24 2015-07-17 Rpgr genska terapija za pigmentnu retinopatiju

Country Status (18)

Country Link
US (2) US10314924B2 (enExample)
EP (2) EP3821912B1 (enExample)
JP (3) JP6654760B2 (enExample)
CN (1) CN107206105A (enExample)
CA (1) CA2991750C (enExample)
CY (1) CY1123793T1 (enExample)
DK (2) DK3191139T3 (enExample)
ES (2) ES2834402T3 (enExample)
FI (1) FI3821912T3 (enExample)
HR (2) HRP20241154T1 (enExample)
HU (2) HUE068183T2 (enExample)
LT (2) LT3191139T (enExample)
PL (2) PL3821912T3 (enExample)
PT (2) PT3191139T (enExample)
RS (2) RS61307B1 (enExample)
SI (2) SI3191139T1 (enExample)
SM (2) SMT202000715T1 (enExample)
WO (1) WO2016014353A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2834402T3 (es) * 2014-07-24 2021-06-17 Massachusetts Eye & Ear Infirmary Terapia génica con RPGR para retinitis pigmentosa
US20190054117A1 (en) * 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
CA2979229A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
EP3697448A1 (en) * 2017-10-20 2020-08-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant aav9-derived vector
SI3710590T1 (sl) * 2017-11-15 2024-10-30 The Regents Of The University Of Michigan Virusni vektorji, ki obsegajo kodirne regije RDH12 in postopke zdravljenja retinalnih distrofij
MX2022011177A (es) * 2020-03-11 2022-12-13 Massachusetts Eye & Ear Infirmary Terapia genica para la degeneracion de la retina asociada a nmnat1.
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0228458B2 (en) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
EP0391960B1 (en) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
WO2001038578A1 (en) * 1999-11-24 2001-05-31 Cornell Research Foundation, Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) * 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
CN105120901A (zh) * 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
ES2834402T3 (es) * 2014-07-24 2021-06-17 Massachusetts Eye & Ear Infirmary Terapia génica con RPGR para retinitis pigmentosa

Also Published As

Publication number Publication date
WO2016014353A1 (en) 2016-01-28
JP2017523239A (ja) 2017-08-17
JP6966532B2 (ja) 2021-11-17
DK3191139T3 (da) 2020-11-16
SMT202400309T1 (it) 2024-11-15
CY1123793T1 (el) 2022-05-27
US20170216454A1 (en) 2017-08-03
DK3821912T3 (da) 2024-08-05
EP3821912B1 (en) 2024-06-12
CN107206105A (zh) 2017-09-26
SI3821912T1 (sl) 2024-10-30
JP7198329B2 (ja) 2022-12-28
PL3191139T3 (pl) 2021-07-05
PT3821912T (pt) 2024-08-01
EP3191139A4 (en) 2018-01-10
EP3821912A1 (en) 2021-05-19
FI3821912T3 (fi) 2024-08-05
LT3191139T (lt) 2021-01-25
LT3821912T (lt) 2024-09-25
JP6654760B2 (ja) 2020-02-26
US11045558B2 (en) 2021-06-29
US10314924B2 (en) 2019-06-11
EP3191139B1 (en) 2020-10-07
SMT202000715T1 (it) 2021-01-05
ES2834402T3 (es) 2021-06-17
PT3191139T (pt) 2020-11-05
PL3821912T3 (pl) 2024-10-28
SI3191139T1 (sl) 2021-03-31
CA2991750C (en) 2023-02-14
HUE052781T2 (hu) 2021-05-28
HRP20241154T1 (hr) 2024-11-22
EP3191139A1 (en) 2017-07-19
JP2022009333A (ja) 2022-01-14
CA2991750A1 (en) 2016-01-28
ES2987090T3 (es) 2024-11-13
HUE068183T2 (hu) 2024-12-28
RS65909B1 (sr) 2024-10-31
JP2020073536A (ja) 2020-05-14
HRP20202023T1 (hr) 2021-03-05
US20200215203A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
US11045558B2 (en) RPGR gene therapy for retinitis pigmentosa
JP6827320B2 (ja) ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法
US20150094360A1 (en) Use of neuroglobin agonist for preventing or treating mitochondrial RCCI and/or RCCIII deficiency disease
Bouaita et al. Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy
Fogerty et al. 174delG mutation in mouse MFRP causes photoreceptor degeneration and RPE atrophy
US20140364488A1 (en) Rpgrip1 gene therapy for leber congenital amaurosis
CA3168365A1 (en) Treating autosomal dominant bestrophinopathies and methods for evaluating same
HK40051900B (en) Rpgr gene therapy for retinitis pigmentosa
HK40051900A (en) Rpgr gene therapy for retinitis pigmentosa
Duong Use Of Induced Pluripotent Stem Cell Models To Elucidate Retinal Disease Pathogenesis And To Develop Gene-Based Therapies
Schwartz Improving AAV Retinal Gene Therapy for Batten Disease
Hickmott rAAV9 mediated PAX6 gene transfer temporarily reverses corneal epithelial thinning in a mouse model of aniridia
Matsuki Development of gene therapy for achromatopsia due to CNGA3 mutations
Mitchell Longitudinal studies and the development of gene therapy for ovine neuronal ceroid lipofuscinoses
Weed Addressing Aav-Mediated Gene Therapy Challenges In The Retina: Readministration, Aav Capsid Optimization, And In Vitro Disease Modeling
Sannan Genetic insights into the role of PAX6 in ocular development
EA044520B1 (ru) Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки
Tracy Ex Vivo Gene Therapy for the Preservation of Retinal and Central Nervous System Structure and Function in a Canine Model of CLN2 Neuronal Ceroid Lipofuscinosis